| Zanubrutinib studied in …STUDIED_INderived121 of 121show fewer |
|---|
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · 121 trials list this drug (85 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06073821Phase 3 · active not recruiting Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697184Phase 1/Phase 2 · recruiting A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06742996Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277231Phase 3 · recruiting A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · 121 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · 121 trials list this drug (85 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840602Phase 2 · recruiting Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · 121 trials list this drug (85 active) | — | — | Lymphoplasmacytic Lymphoma,Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029309Phase 1/Phase 2 · recruiting Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341191Phase 2 · recruiting Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06735664Phase 1 · recruiting Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation · 121 trials list this drug (85 active) | — | — | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · 121 trials list this drug (85 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739459Phase 2 · not yet recruiting Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06634589Phase 1/Phase 2 · recruiting A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies · 121 trials list this drug (85 active) | — | — | Malignant Neoplasm,B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07799220Phase 2 · not yet recruiting A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07812246Phase 2 · not yet recruiting Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326308recruiting Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Follicular Lymphoma,Marginal Zone Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973811Phase 2 · recruiting ZR-MTX for PIOL Phase II Trial · 121 trials list this drug (85 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03824483Phase 2 · active not recruiting Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05976763Phase 3 · recruiting Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07321652Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561347Phase 2 · recruiting Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07734038Phase 2 · recruiting Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04170283Phase 3 · active not recruiting A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441214active not recruiting Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515238Phase 2 · active not recruiting Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06849713Phase 2 · recruiting Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389293Phase 2 · recruiting A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma · 121 trials list this drug (85 active) | — | — | Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07169331Phase 4 · active not recruiting A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05640102recruiting Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563505Phase 2 · recruiting A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma · 121 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · 121 trials list this drug (85 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717177Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · 121 trials list this drug (85 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · 121 trials list this drug (85 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Splenic Marginal Zone Lymphoma,Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558604Phase 2 · recruiting Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06637501Phase 2 · active not recruiting A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07690761Phase 2 · enrolling by invitation Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant · 121 trials list this drug (85 active) | — | — | Hairy Cell Leukemia,Hairy Cell Leukemia Variant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850495Phase 1 · active not recruiting Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824701Phase 1 · active not recruiting Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07674810Phase 2 · not yet recruiting A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04277637Phase 1 · active not recruiting Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07271667Phase 2 · recruiting A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06167785Phase 2 · recruiting A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594899Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04002297Phase 3 · active not recruiting A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04458610Phase 2 · active not recruiting Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730542Phase 1 · recruiting Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma · 121 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504199Phase 2 · active not recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07261163Phase 2 · recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05718869Phase 2 · active not recruiting Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06839053Phase 2 · recruiting Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05068440Phase 2 · completed Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03336333Phase 3 · active not recruiting A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06067048Phase 2 · active not recruiting Zanubrutinib in Primary Cold Agglutinin Disease · 121 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05681195Phase 2 · recruiting Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas · 121 trials list this drug (85 active) | — | — | Malignant Neoplasm,Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05873712Phase 2 · recruiting Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome · 121 trials list this drug (85 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma,Transformed Non-Hodgkin Lymphoma,Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04282018Phase 1/Phase 2 · completed Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab · 121 trials list this drug (85 active) | — | — | Solid Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854003Phase 2 · recruiting BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332017Phase 2 · completed A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma · 121 trials list this drug (85 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377578Phase 3 · recruiting A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116437Phase 2 · completed Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Mantle Cell Lymphoma,Marginal Zone Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665530Phase 1 · completed A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Myelodysplastic Syndrome,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06846463Phase 2 · recruiting Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05952037Phase 2 · active not recruiting A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07283965not yet recruiting Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07052695Phase 1/Phase 2 · recruiting Mosunetuzumab for CLL MRD Clearance · 121 trials list this drug (85 active) | — | — | Leukemia,Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06803693Phase 2 · recruiting Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07270835Phase 4 · recruiting Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05168930Phase 2 · recruiting Zanubrutinib and Venetoclax in CLL (ZANU-VEN) · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04172246Phase 1/Phase 2 · completed Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07233720recruiting Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma · 121 trials list this drug (85 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · 121 trials list this drug (85 active) | — | — | Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06375733Phase 1/Phase 2 · recruiting A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012980Phase 2 · not yet recruiting Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003464Phase 2 · not yet recruiting Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04436107Phase 1 · completed Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06942507NA · not yet recruiting Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04668365Phase 2 · suspended Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05635162Phase 2 · recruiting Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734016Phase 3 · completed A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06695013Phase 2 · recruiting Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03189524Phase 1 · completed A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06646666Phase 2 · not yet recruiting ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT · 121 trials list this drug (85 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06669143Phase 2 · not yet recruiting Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02569476Phase 1 · completed BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03053440Phase 3 · completed A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03145064Phase 2 · completed Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03206918Phase 2 · completed Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03206970Phase 2 · completed Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332173Phase 2 · completed Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03520920Phase 2 · completed BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03846427Phase 2 · completed Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma · 121 trials list this drug (85 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551963Phase 1 · completed Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052854no longer available A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma,Transformed B-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06341556Phase 2 · recruiting A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06554600Phase 2 · recruiting A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06547944Phase 1 · active not recruiting Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06489184unknown The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06474481Phase 2 · not yet recruiting Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06367374Phase 2 · not yet recruiting MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136351Phase 2 · recruiting A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma · 121 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05979948Phase 2 · unknown A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia · 121 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896007Phase 2 · unknown Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT · 121 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887726Phase 2 · unknown Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02914938Phase 1 · terminated A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma · 121 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797948NA · unknown GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 121 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05596097Phase 2 · unknown Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835870Phase 2 · unknown Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05117814NA · unknown Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma · 121 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02795182Phase 1 · completed Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies · 121 trials list this drug (85 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343120Phase 1/Phase 2 · completed Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies · 121 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05290337Phase 2 · unknown ZR-CHOP in DLBCL With Specific Gene Abnormality · 121 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05200312Phase 2 · unknown A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899453Phase 2 · unknown Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL · 121 trials list this drug (85 active) | — | — | Primary Vitreoretinal Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899570Phase 2 · unknown Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma · 121 trials list this drug (85 active) | — | — | Intravascular Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04705129Phase 2 · unknown Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL · 121 trials list this drug (85 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |